Portage Biotech (NASDAQ:ALP) Upgraded by Wall Street Zen to Hold Rating

Wall Street Zen upgraded shares of Portage Biotech (NASDAQ:ALP) to a hold rating in a research note published on Saturday,Wall Street Zen reports.

Several other equities analysts have also recently commented on ALP. Zacks Research raised Portage Biotech to a “hold” rating in a report on Tuesday, August 18th. Weiss Ratings restated a “sell (e+)” rating on shares of Portage Biotech in a research note on Friday, July 24th. Finally, HC Wainwright initiated coverage on Portage Biotech in a research report on Monday, August 17th. They issued a “neutral” rating and a $12.50 target price for the company. Two investment analysts have rated the stock with a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Portage Biotech currently has an average rating of “Reduce” and an average price target of $12.50.

Portage Biotech Price Performance

Shares of Portage Biotech stock opened at $4.04 on Friday. The company has a debt-to-equity ratio of 0.01, a current ratio of 0.31 and a quick ratio of 0.31. The company has a market cap of $6.26 million, a PE ratio of -0.49 and a beta of 0.54. The firm has a fifty day moving average price of $10.78 and a two-hundred day moving average price of $14.90. Portage Biotech has a fifty-two week low of $3.20 and a fifty-two week high of $690.00.

Portage Biotech (NASDAQ:ALP) last announced its quarterly earnings data on Thursday, July 16th. The company reported $23.75 EPS for the quarter. The company had revenue of $0.05 million for the quarter. Analysts expect that Portage Biotech will post -14 EPS for the current year.

Portage Biotech Company Profile

Portage Biotech (NASDAQ:ATON) is a biotechnology company focused on acquiring, developing and advancing therapeutic candidates and platform technologies. The company concentrates its development efforts primarily in areas such as oncology, immunology/inflammation and infectious disease, seeking to move programs from discovery and preclinical stages into clinical development through subsidiary companies and collaborative arrangements.

Portage structures its operations to support a diversified pipeline, advancing both small molecules and biologics by funding preclinical research, conducting clinical trials, and managing regulatory interactions.